Malcolm Brenner

From Wikipedia, the free encyclopedia

Malcolm K. Brenner is a British clinical scientist working mostly in the field of gene therapy and immunotherapy applied to malignancy.

He received his medical degree and subsequent Ph.D. from Cambridge University, England. He became part of the UK brain-drain in the 1970s, when he left the UK to work in St. Jude Children's Research Hospital in Memphis.

There, he conducted one of the first human gene therapy studies when he transduced bone-marrow stem cells with a retroviral vector with the intention of marking them to study their survival and fate. This seminal study demonstrated that engrafted bone marrow stem cells contribute to long-term hematopoiesis and also that contaminating tumor cells in autografts can cause relapse.

More recently, his group has become interested in the genetic-modification of T-cells for cancer therapy, cancer vaccines and monoclonal antibodies.

He currently works in the Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas.

He was also the first to suggest the next-in-line effect.

[edit] References

1. Brenner's origins in the UK. Retrieved on 2007-05-30.
   
2. "Giant Step for Gene Therapy"", Time Magazine, Initial work on gene marking. Retrieved on 2007-05-30. 
   
3. Center for Cell and Gene Therapy. Retrieved on 2007-05-30.